新辅助化疗增强膀胱尿路上皮癌抗肿瘤T细胞应答
这项前瞻性研究分析了40例肌层浸润性膀胱尿路上皮癌患者新辅助化疗前后肿瘤引流前哨淋巴结中T细胞亚群的变化。研究发现NAC治疗后CD8+效应T细胞耗竭减少、细胞毒性增加,完全缓解患者的这些细胞为功能性终末效应细胞;CD4+效应T细胞中肿瘤特异性克隆扩增增加,而调节性T细胞频率呈剂量依赖性下降且效应分子表达降低。完全缓解患者效应T细胞与活化调节性T细胞比值更高,提示NAC通过激活效应T细胞分支并削弱抑制性Treg影响来增强抗肿瘤免疫应答。
要点
- NAC后前哨淋巴结CD8+效应T细胞耗竭减少且细胞毒性增加
- 完全缓解患者CD8+效应T细胞经表观遗传分析显示为功能性终末效应细胞
- NAC使Treg频率呈剂量依赖性下降并降低剩余Treg效应分子表达
核心结论
- 新辅助化疗通过激活T细胞效应分支并削弱抑制性调节性T细胞的影响来增强抗肿瘤免疫应答。
研究设计与样本
- 前瞻性研究,分析40例肌层浸润性膀胱尿路上皮癌患者新辅助化疗后肿瘤引流前哨淋巴结的T细胞亚群。
主要发现
- NAC治疗后CD8+效应T细胞耗竭减少而细胞毒性增加,完全缓解患者中这些细胞为功能性终末效应细胞。
- CD4+效应T细胞中,NAC与肿瘤特异性前哨淋巴结来源细胞的克隆扩增增加相关。
- NAC对调节性T细胞有减弱效应,Treg频率呈剂量依赖性下降,剩余Treg效应分子表达降低。
- 多色流式细胞术分析显示完全缓解患者效应T细胞与活化Treg比值更高。
关键数值与推荐
- 完全缓解患者CD8+效应T细胞经表观遗传分析显示为功能性终末效应细胞。
- NAC治疗后Treg频率呈剂量依赖性下降。
- 完全缓解患者效应T细胞与活化Treg比值更高,促进抗肿瘤T细胞活化。
临床怎么用
- 结果提示NAC除直接细胞毒作用外可增强膀胱癌抗肿瘤免疫应答,支持其免疫调节效应。
- 前哨淋巴结T细胞亚群变化可能作为评估NAC免疫效应的研究性指标。
局限性
- 研究为40例患者的前瞻性分析,样本量有限。
- 摘要未报告随访时长、具体统计阈值及混杂因素控制等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Evidence indicates that neoadjuvant chemotherapy (NAC) may promote antitumour immune responses by activating T cells. The tumour-draining sentinel node (SN) is a key site to study tumour-specific T cell activation, being the primary immunological barrier against the tumour. In this prospective study, we set out to elucidate the effects of NAC on T cell subsets in the SNs of patients with muscle-invasive urothelial bladder cancer. We found that CD8+ effector T (Teff) cell exhaustion was reduced after NAC treatment, while cytotoxicity was increased. Additionally, in complete responders (CR patients), these cells were functionally committed effectors, as displayed by epigenetic analysis. In CD4+ Teffs, NAC treatment was associated with increased clonal expansion of tumour-specific SN-derived cells, as demonstrated by a specific cell reactivity assay. In contrast, we observed an attenuating effect of NAC on regulatory T cells (Tregs) with a dose-dependent decrease in Treg frequency and reduced effector molecule expression in the remaining Tregs. In addition, multicolour flow cytometry analysis revealed that CR patients had higher Teff to activated Treg ratio, promoting antitumoural T cell activation. These results suggest that NAC reinforces the antitumour immune response by activating the effector arm of the T cell compartment and diminishing the influence of suppressive Tregs. PATIENT SUMMARY: In this report, we analysed the effect of chemotherapy on immune cell subsets of 40 patients with advanced bladder cancer. We found that chemotherapy has a positive effect on immune effector T cells, whereas an opposite, diminishing effect was observed for immune-suppressive regulatory T cells. We conclude that chemotherapy reinforces the antitumour immune response in bladder cancer patients.
引用
- Krantz D, Hartana CA, Winerdal ME, et al. Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. Eur Urol. 2018. PMID: 30025882. doi:10.1016/j.eururo.2018.06.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。